RT Book, Section
A1 Blaha, Michael J.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193133379
T1 Overview: Lipid Disorders
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193133379
RD 2024/04/25
AB The  “Lipid  Hypothesis”  of  CVD—stating  that  cholesterol  is  causal  in  the  development  of  atherosclerotic  CVD  (ASCVD)  and  that  lowering  cholesterol  is  associated  with  lower  cardiovascular  event  rates—is  widely  accepted  throughout  the  medical  community.  For  patients  with  known  CVD  (secondary  prevention),  studies  have  shown  that  cholesterol  lowering  leads  to  a  consistent  reduction  in  total  mortality  and  in  recurrent  cardiovascular  events  in  men  and  women;  other  studies  have  documented  lowered  mortality  and  events  in  middle-aged  and  older  patients.  Among  patients  without  CVD  (primary  prevention),  the  data  are  generally  consistent,  with  rates  of  cardiovascular  events,  heart  disease  mortality,  and  all-cause  mortality  differing  among  studies.  Treatment  guidelines  have  been  designed  to  assist  clinicians  in  selecting  patients  for  cholesterol-lowering  therapy  based  predominantly  on  their  overall  risk  of  developing  CVD  as  well  as  their  baseline  cholesterol  levels.